401 related articles for article (PubMed ID: 26534878)
1. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
3. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
5. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
7. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma.
Li H; Ren B; Yu S; Gao H; Sun PL
BMC Cancer; 2023 Feb; 23(1):161. PubMed ID: 36797681
[TBL] [Abstract][Full Text] [Related]
10. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis?
Jeong YJ; Lee KS; Kim J; Shim YM; Han J; Kwon OJ
AJR Am J Roentgenol; 2004 Aug; 183(2):283-9. PubMed ID: 15269013
[TBL] [Abstract][Full Text] [Related]
11. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
Kim DJ; Yang WI; Kim SH; Park IK; Chung KY
Eur J Cardiothorac Surg; 2005 Oct; 28(4):611-6. PubMed ID: 16125946
[TBL] [Abstract][Full Text] [Related]
12. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
13. Corticomedullary differentiation and maturational arrest in thymomas.
Ströbel P; Hartmann E; Rosenwald A; Kalla J; Ott G; Friedel G; Schalke B; Kasahara M; Tomaru U; Marx A
Histopathology; 2014 Mar; 64(4):557-66. PubMed ID: 24236644
[TBL] [Abstract][Full Text] [Related]
14. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.
Marx A; Ströbel P; Badve SS; Chalabreysse L; Chan JK; Chen G; de Leval L; Detterbeck F; Girard N; Huang J; Kurrer MO; Lauriola L; Marino M; Matsuno Y; Molina TJ; Mukai K; Nicholson AG; Nonaka D; Rieker R; Rosai J; Ruffini E; Travis WD
J Thorac Oncol; 2014 May; 9(5):596-611. PubMed ID: 24722150
[TBL] [Abstract][Full Text] [Related]
15. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging of thymic epithelial tumors.
Kushihashi T; Fujisawa H; Munechika H
Crit Rev Diagn Imaging; 1996 Aug; 37(3):191-259. PubMed ID: 8872410
[TBL] [Abstract][Full Text] [Related]
17. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas.
Sadohara J; Fujimoto K; Müller NL; Kato S; Takamori S; Ohkuma K; Terasaki H; Hayabuchi N
Eur J Radiol; 2006 Oct; 60(1):70-9. PubMed ID: 16766154
[TBL] [Abstract][Full Text] [Related]
18. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
19. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
20. Unique correlation between GTF2I mutation and spindle cell morphology in thymomas (type A and AB thymomas).
Wells K; Lamrca A; Papaxoinis G; Wallace A; Quinn AM; Summers Y; Nonaka D
J Clin Pathol; 2023 Jul; 76(7):463-466. PubMed ID: 35039450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
